The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gangliosidosis gene therapy PBGM01 on clinical hold pending further assessment of the risks associated with its delivery device, delaying the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results